[go: up one dir, main page]

ECSP11011040A - Derivados de carbamatos de alquil-heterociclos, su preparación y su aplicación en terapéutica - Google Patents

Derivados de carbamatos de alquil-heterociclos, su preparación y su aplicación en terapéutica

Info

Publication number
ECSP11011040A
ECSP11011040A EC2011011040A ECSP11011040A ECSP11011040A EC SP11011040 A ECSP11011040 A EC SP11011040A EC 2011011040 A EC2011011040 A EC 2011011040A EC SP11011040 A ECSP11011040 A EC SP11011040A EC SP11011040 A ECSP11011040 A EC SP11011040A
Authority
EC
Ecuador
Prior art keywords
group
pyrazoloneone
optionally substituted
trifluoromethyl
integer equal
Prior art date
Application number
EC2011011040A
Other languages
English (en)
Inventor
Corinne Veronique
Julien Vache
Mourad Saady
Ahmed Abouabdellah
Nathalie Chereze
Aude Fayol
Philippe Yaiche
Original Assignee
Sanofi Aventis
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=40852115&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ECSP11011040(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Sanofi Aventis filed Critical Sanofi Aventis
Publication of ECSP11011040A publication Critical patent/ECSP11011040A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D407/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00
    • C07D407/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Cardiology (AREA)
  • Immunology (AREA)
  • Pulmonology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Virology (AREA)
  • Otolaryngology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Hospice & Palliative Care (AREA)
  • Ophthalmology & Optometry (AREA)
  • Anesthesiology (AREA)
  • Vascular Medicine (AREA)
  • Epidemiology (AREA)

Abstract

Compuesto que corresponde a la fórmula general (I): en la que R2 representa un átomo de hidrógeno, de flúor o un grupo hidroxilo, ciano, trifluorometilo, alquilo-C1-6, alcoxi-C1-6, NR8R9 ; n representa un número entero igual a 1, 2 ó 3 y m representa un número entero igual a 1 ó 2; A representa un enlace covalente o un grupo alquileno-C1-8 ; R1 representa un grupo fenilo, piridinilo, piridacinilo, pirimidinilo, piracinilo, triacinilo, naftalenilo, quinolinilo, isoquinolinilo, ftalacinilo, quinazolinilo, quinoxalinilo, cinolinilo, naftiridinilo, estando este grupo sustituido opcionalmente ; R3 representa un átomo de hidrógeno, de flúor, un grupo alquilo-C1-6 o un grupo trifluorometilo ; R4 representa un grupo elegido entre un furanilo, pirrolilo, tienilo, isotiazolilo, oxazolilo, isoxazolilo, pirazolilo, oxadiazolilo, tiadiazolilo, imidazol, triazolilo, tetrazolilo, oxazolona, oxazolidinona, isoxazolona, isoxazolidinona, isotiazolona, isotiazolidinona, imidazolona, imidazolidinona, pirazolona, pirazolidinona, oxadiazolona, tiadiazolona, triazolona, estando este grupo sustituido opcionalmente; en el estado de base o de sal de adición a un ácido. Uso en terapéutica.
EC2011011040A 2008-11-14 2011-05-11 Derivados de carbamatos de alquil-heterociclos, su preparación y su aplicación en terapéutica ECSP11011040A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR0806371A FR2938537B1 (fr) 2008-11-14 2008-11-14 Derives de carbamates d'alkyl-heterocycles, leur preparation et leur application en therapeutique.

Publications (1)

Publication Number Publication Date
ECSP11011040A true ECSP11011040A (es) 2011-06-30

Family

ID=40852115

Family Applications (1)

Application Number Title Priority Date Filing Date
EC2011011040A ECSP11011040A (es) 2008-11-14 2011-05-11 Derivados de carbamatos de alquil-heterociclos, su preparación y su aplicación en terapéutica

Country Status (27)

Country Link
US (1) US8716289B2 (es)
EP (1) EP2356108B1 (es)
JP (1) JP5560287B2 (es)
KR (1) KR20110083743A (es)
CN (1) CN102216291B (es)
AR (1) AR074119A1 (es)
AU (1) AU2009315448B2 (es)
BR (1) BRPI0921057A2 (es)
CA (1) CA2743558C (es)
CL (1) CL2011001122A1 (es)
CO (1) CO6331472A2 (es)
CR (1) CR20110246A (es)
EA (1) EA019742B1 (es)
EC (1) ECSP11011040A (es)
FR (1) FR2938537B1 (es)
IL (1) IL212830A (es)
MA (1) MA32884B1 (es)
MX (1) MX2011005124A (es)
NI (1) NI201100095A (es)
NZ (1) NZ592740A (es)
PA (1) PA8848901A1 (es)
PE (1) PE20120217A1 (es)
SV (1) SV2011003895A (es)
TW (1) TWI462919B (es)
UY (1) UY32246A (es)
WO (1) WO2010055267A1 (es)
ZA (1) ZA201103516B (es)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2934265B1 (fr) * 2008-07-23 2010-07-30 Sanofi Aventis Derives de carbamates d'alkylthiazoles, leur preparation et leur application en therapeutique
US20130150346A1 (en) 2010-01-08 2013-06-13 Quest Ventures Ltd. Use of FAAH Inhibitors for Treating Parkinson's Disease and Restless Legs Syndrome
WO2011123719A2 (en) 2010-03-31 2011-10-06 Ironwood Pharmaceuticals, Inc. Use of faah inhibitors for treating abdominal, visceral and pelvic pain
FR2960875B1 (fr) 2010-06-04 2012-12-28 Sanofi Aventis Derives de carbamates d'hexafluoroisopropyle, leur preparation et leur application en therapeutique
GB201309508D0 (en) * 2013-05-28 2013-07-10 Redx Pharma Ltd Compounds
ITMI20131180A1 (it) 2013-07-15 2015-01-16 Fond Istituto Italiano Di Tecnologia O-alchil triazolil carbammati come inibitori di idrolasi delle ammidi degli acidi grassi (faah)
MX2017001097A (es) * 2014-07-28 2017-04-27 Sumitomo Chemical Co Compuesto de amida y su uso para control de artropodos nocivos.
CN111171315B (zh) * 2020-02-25 2021-08-17 常熟理工学院 一种结晶性n-取代聚硫代氨基甲酸酯及其制备方法

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2501506C (en) * 2002-10-07 2014-02-11 Daniele Piomelli Modulation of anxiety through blockade of anandamide hydrolysis
FR2854633B1 (fr) * 2003-05-07 2005-06-24 Sanofi Synthelabo Derives de piperidinyl-et piperazinyl-alkylcarbamates, leur preparation et leur application en therapeutique
DE602005009811D1 (de) 2004-03-26 2008-10-30 Hoffmann La Roche Tetrahydrocarbazole und derivate
SE0401656D0 (sv) 2004-06-24 2004-06-24 Astrazeneca Ab Chemical compounds
KR20070050475A (ko) * 2004-08-11 2007-05-15 교린 세이야꾸 가부시키 가이샤 신규 환상 아미노 안식향산 유도체
US20070078135A1 (en) * 2005-04-18 2007-04-05 Neurogen Corporation Substituted heteroaryl CB1 antagonists
GB0510140D0 (en) 2005-05-18 2005-06-22 Addex Pharmaceuticals Sa Novel compounds B2
WO2007146761A2 (en) * 2006-06-12 2007-12-21 Neurogen Corporation Diaryl pyrimidinones and related compounds
KR101580482B1 (ko) 2007-11-16 2015-12-28 인사이트 홀딩스 코포레이션 야누스 키나제 억제제로서의 ４－피라졸릴－ｎ－아릴피리미딘－２－아민 및 ４－피라졸릴－ｎ－헤테로아릴피리미딘－２－아민
FR2934265B1 (fr) * 2008-07-23 2010-07-30 Sanofi Aventis Derives de carbamates d'alkylthiazoles, leur preparation et leur application en therapeutique

Also Published As

Publication number Publication date
AR074119A1 (es) 2010-12-22
NI201100095A (es) 2011-12-14
MX2011005124A (es) 2011-05-30
EP2356108A1 (fr) 2011-08-17
BRPI0921057A2 (pt) 2018-10-16
NZ592740A (en) 2013-03-28
UY32246A (es) 2010-06-30
MA32884B1 (fr) 2011-12-01
JP2012508785A (ja) 2012-04-12
AU2009315448A1 (en) 2010-05-20
CO6331472A2 (es) 2011-10-20
EA201170686A1 (ru) 2011-12-30
PA8848901A1 (es) 2010-06-28
CA2743558A1 (fr) 2010-05-20
SV2011003895A (es) 2011-08-15
TWI462919B (zh) 2014-12-01
IL212830A (en) 2014-11-30
JP5560287B2 (ja) 2014-07-23
EA019742B1 (ru) 2014-05-30
CA2743558C (fr) 2017-02-14
KR20110083743A (ko) 2011-07-20
FR2938537A1 (fr) 2010-05-21
ZA201103516B (en) 2012-07-25
FR2938537B1 (fr) 2012-10-26
US20120015950A1 (en) 2012-01-19
EP2356108B1 (fr) 2014-10-15
WO2010055267A1 (fr) 2010-05-20
IL212830A0 (en) 2011-07-31
US8716289B2 (en) 2014-05-06
CR20110246A (es) 2012-06-15
CN102216291A (zh) 2011-10-12
AU2009315448B2 (en) 2015-07-16
TW201026692A (en) 2010-07-16
CN102216291B (zh) 2016-08-03
CL2011001122A1 (es) 2011-09-16
PE20120217A1 (es) 2012-03-12

Similar Documents

Publication Publication Date Title
ECSP11011040A (es) Derivados de carbamatos de alquil-heterociclos, su preparación y su aplicación en terapéutica
CO6351789A2 (es) Derivados de carbamatos de alquiltiazoles, su preparacion y su aplicacion en terapeutica
RU2009118281A (ru) Гетероциклические ингибиторы мек и способы их применения
EA200800182A1 (ru) Циклические анилинопиридинотриазины в качестве ингибиторов gsk-3
AR047817A1 (es) Derivados de aril- y heteroarilpiperidincarboxilatos, su preparacion y su aplicacion en terapeutica
AR076563A1 (es) Derivados de ciclopenta[c]pirrol-2-carboxilatos, su preparacion y su apli-cacion en terapeutica
BRPI1007456A2 (pt) derivados de azaespiranil-alquilcarbamatos de compostos heterocíclicos com 5 membros, o respectivo preparo e a respectiva aplicação em terapêutica
UY30603A1 (es) Derivados de 2-aril-6-fenil-imidazo[1, 2-a]piridinas, su preparacion y su aplicacion en terapéutica
UA105671C2 (uk) Фармацевтична композиція, яка містить похідне хіноліну
CO6251235A2 (es) Compuestos derivados de azetidinas su preparacion y su aplicacion en terapeutica
CO5700820A2 (es) Derivados de dioxan-2-alquilcarbamatos, su preparacion y su aplicacion en terapeutica
AR076561A1 (es) Derivados de ciclopenta (c) pirrol-2- carboxilatos, su preparacion y su aplicacion en terapeutica
AR058077A1 (es) Derivados de acidos fenoxiaceticos
MX2008016558A (es) Preparacion y aplicacion terapéutica de derivados de 2-benzoil-imidazopiridinas.
JP2010500432A5 (es)
DE60316669D1 (de) Mit säure abbaubare harzzusammensetzungen mit ketenaldehyd-copolymer
NO20083955L (no) Nye kromen-2-on-derivater og deres anvendelse som monoaminneurotransmittergjenopptaksinhibitorer
PE20090602A1 (es) Nuevos compuestos
WO2009021957A3 (en) Tricyclic heterocyclic compounds as gaba a modulators
CA2445322A1 (en) Use of the abc expression promoting agent pioglitazone for the treatment of arteriosclerosis obliterans
ECSP088182A (es) Derivados de 5-piridazinil-1-azabiciclo[3.2.1]octano, su preparación y su aplicación en terapéutica
PE20110539A1 (es) Derivados de 1h-(piperidin-4-il) pirazol-5-ona como inhibidores de fosfodiesterasa de tipo 4
TW200942538A (en) 2-benzoylimidazo[1,2-a]pyridine derivatives, preparation thereof and therapeutic use thereof
AR067879A1 (es) Inhibidores de epoxido hidrolasa solubles para el tratamiento del sindrome metabolico y trastornos relacionados
JP2006008600A5 (es)